147 related articles for article (PubMed ID: 26314905)
1. Overexpression of PDZ-binding kinase confers malignant phenotype in prostate cancer via the regulation of E2F1.
Chen JH; Liang YX; He HC; Chen JY; Lu JM; Chen G; Lin ZY; Fu X; Ling XH; Han ZD; Jiang FN; Zhong WD
Int J Biol Macromol; 2015 Nov; 81():615-23. PubMed ID: 26314905
[TBL] [Abstract][Full Text] [Related]
2. E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer.
Liang YX; Lu JM; Mo RJ; He HC; Xie J; Jiang FN; Lin ZY; Chen YR; Wu YD; Luo HW; Luo Z; Zhong WD
Int J Oncol; 2016 Apr; 48(4):1650-8. PubMed ID: 26891801
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
5. PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion.
Brown-Clay JD; Shenoy DN; Timofeeva O; Kallakury BV; Nandi AK; Banerjee PP
Oncotarget; 2015 Jun; 6(17):15594-609. PubMed ID: 25909225
[TBL] [Abstract][Full Text] [Related]
6. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
7. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma.
Yang YF; Pan YH; Cao Y; Fu J; Yang X; Zhang MF; Tian QH
Oncotarget; 2017 Jul; 8(29):47195-47205. PubMed ID: 28525379
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.
Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Br J Cancer; 2017 Jan; 116(2):218-226. PubMed ID: 27898655
[TBL] [Abstract][Full Text] [Related]
9. Decreased HoxD10 Expression Promotes a Proliferative and Aggressive Phenotype in Prostate Cancer.
Mo RJ; Lu JM; Wan YP; Hua W; Liang YX; Zhuo YJ; Kuang QW; Liu YL; He HC; Zhong WD
Curr Mol Med; 2017; 17(1):70-78. PubMed ID: 28231752
[TBL] [Abstract][Full Text] [Related]
10. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
11. [Effect of transcription factor E2F1 expression on the invasion of prostate cancer].
Bi XC; Pu XY; Liu JM; Huang S
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(36):2856-2859. PubMed ID: 29050152
[No Abstract] [Full Text] [Related]
12. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
[TBL] [Abstract][Full Text] [Related]
13. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
14. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma.
Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H
Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.
Ling XH; Han ZD; Xia D; He HC; Jiang FN; Lin ZY; Fu X; Deng YH; Dai QS; Cai C; Chen JH; Liang YX; Zhong WD; Wu CL
Mol Biol Rep; 2014 May; 41(5):2779-88. PubMed ID: 24452717
[TBL] [Abstract][Full Text] [Related]
16. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
17. Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer.
Luo HW; Chen QB; Wan YP; Chen GX; Zhuo YJ; Cai ZD; Luo Z; Han ZD; Liang YX; Zhong WD
Biomed Pharmacother; 2016 Mar; 78():116-120. PubMed ID: 26898432
[TBL] [Abstract][Full Text] [Related]
18. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
[TBL] [Abstract][Full Text] [Related]
19. Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene.
Schayek H; Bentov I; Rotem I; Pasmanik-Chor M; Ginsberg D; Plymate SR; Werner H
Growth Horm IGF Res; 2010 Feb; 20(1):68-72. PubMed ID: 19703789
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.
Wan Y; Zeng ZC; Xi M; Wan S; Hua W; Liu YL; Zhou YL; Luo HW; Jiang FN; Zhong WD
Hum Pathol; 2015 Feb; 46(2):295-303. PubMed ID: 25532941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
